- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04062370
Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion
Different Regimens of Ranibizumab Treatment for Macular Edema Secondary to Retinal Vein Occlusion: a Randomized and Controlled Clinical Study.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510060
- Chuangxin Huang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with RVO-ME diagnosed definitely by FFA and OCT, with CMT > 300μm; BCVA from 20/200 to 20/40 (including 20/200 and 20/40), with a degree of myopia ≤-6 diopter (diopter, D);
- Patients with a course of RVO ≤ 12 weeks; Patients who have not received laser, intraocular or systemic anti-VEGF treatments or long-acting hormone intraocular, periocular or systemic treatments since the onset of RVO;
- Patients who are voluntary to sign and date the informed consent form approved by the Ethics Review Committee prior to the conduct of the relevant study steps.
Exclusion Criteria:
- Patients with a course of disease > 12 weeks;
- Patients treated with any anti-angiogenic medicines for either eye within 3 months before the baseline; or patients currently in treatment with systemic anti-angiogenic drugs;
- Patients with their study eyes treated with panretinal photocoagulation (PRP) previously;
- Patients previously participating in other clinical trials 3 months before the baseline;
- Patients with severely opacity of refractive media affecting laser treatment and observation;
- Patients with other ophthalmic diseases affecting visual prognosis, such as corneal disease, glaucoma, severe cataract, uveitis, other fundus diseases, etc.
- Patients with in any condition where intravitreal injection is unacceptable;
- Patients identified by the investigator to be medically or mentally unstable: complicated with cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases or mental disease; Women who are pregnant or preparing for pregnancy or in lactation, etc.
- Patients with any history may interfere with the results of the trial or increase the risk of the patient (assessed by the investigator) ;
- Patients who are in poor compliance and unable to strictly implement the protocol (assessed by the investigator).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1+PRN
Intravitreal injection of Ranibizumab 0.5 mg (IVR): initial injection for 1 time ( month 1), and then IVR is required if central macular thickness (CMT) greater than 300 μm during the follow-up observation (Pro re nata, PRN, means if necessary). After 6 months follow-up, patients in this arm will be randomly divided to receive IVR PRN only or laser photocoagulation combined with IVR PRN. IVR PRN only: patient will receive IVR PRN if CMT greater than 300 μm during the follow-up observation (PRN) after month 6. Laser photocoagulation with IVR PRN: patient will receive laser photocoagulation for non-perfusion area according to FFA results after month 6, and then received IVR PRN if CMT greater than 300 μm. |
Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6.
Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.
Other Names:
After month 6, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN according the re-randomization at month 6.
|
Active Comparator: 3+PRN
Intravitreal injection of Ranibizumab 0.5 mg (IVR): initial injection for 3 consecutive times ( months 1, 2 and 3 ),and then IVR is required if CMT greater than 300 μm during the follow-up observation (PRN). After 6 months follow-up, patients in this arm will be randomly divided to receive IVR PRN only or laser photocoagulation combined with IVR PRN. IVR PRN only: patient will receive IVR PRN if CMT greater than 300 μm during the follow-up observation (PRN) after month 6. Laser photocoagulation with IVR PRN: patient will receive laser photocoagulation for non-perfusion area according to FFA results after month 6, and then received IVR PRN if CMT greater than 300 μm. |
Patients will receive intravitreal injection of Ranibizumab 0.5 mg (1+PRN or 3+PRN) according to the study until month 6.
Then, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN after month 6.
Other Names:
After month 6, patients will received Ranibizumab PRN only or laser photocoagulation with Ranibizumab PRN according the re-randomization at month 6.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
best-corrected visual acuity (BCVA) at month 6
Time Frame: Month 6 after first treatment
|
best-corrected visual acuity (BCVA) at month 6
|
Month 6 after first treatment
|
Central macular thickness (CMT) at month 6 (3) the number of intravitreal injections of Ranibizumab at month 6
Time Frame: Month 6 after first treatment
|
Central macular thickness (CMT) at month 6
|
Month 6 after first treatment
|
the number of intravitreal injections of Ranibizumab at month 6
Time Frame: Month 6 after first treatment
|
the number of intravitreal injections of Ranibizumab at month 6
|
Month 6 after first treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
best-corrected visual acuity (BCVA) at month 12
Time Frame: Month 12 after first treatment
|
best-corrected visual acuity (BCVA) at month 12
|
Month 12 after first treatment
|
the number of intravitreal injections of Ranibizumab at month 12
Time Frame: Month 12 after first treatment
|
the number of intravitreal injections of Ranibizumab at month 12
|
Month 12 after first treatment
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
best-corrected visual acuity (BCVA) during the follow-up
Time Frame: during the follow-up for up to 12 months.
|
best-corrected visual acuity (BCVA) during the follow-up
|
during the follow-up for up to 12 months.
|
intraocular pressure during the follow-up
Time Frame: during the follow-up for up to 12 months.
|
intraocular pressure during the follow-up
|
during the follow-up for up to 12 months.
|
central macular thickness during the follow-up
Time Frame: during the follow-up for up to 12 months.
|
central macular thickness during the follow-up
|
during the follow-up for up to 12 months.
|
posterior choroidal thickness during the follow-up
Time Frame: during the follow-up for up to 12 months.
|
posterior choroidal thickness during the follow-up
|
during the follow-up for up to 12 months.
|
The results of angio-optical coherence tomography (angio-OCT) examination during the follow-up
Time Frame: during the follow-up for up to 12 months.
|
The results of angio-OCT examination, including area of non-perfusion and neovascularization.
|
during the follow-up for up to 12 months.
|
Fundus fluorescein angiography (FFA) examination results during the follow-up
Time Frame: during the follow-up for up to 12 months.
|
FFA examination results during the follow-up, including area of non-perfusion and neovascularization.
|
during the follow-up for up to 12 months.
|
Microperimetry during the follow-up
Time Frame: during the follow-up for up to 12 months.
|
Changes in posterior pole found by microperimetry
|
during the follow-up for up to 12 months.
|
Electroretinogram (ERG) during the follow-up
Time Frame: during the follow-up for up to 12 months.
|
Amplitudes and implicit times of the a wave and b wave of ERG during the follow-up
|
during the follow-up for up to 12 months.
|
adverse events occurring in the follow-up
Time Frame: during the follow-up for up to 12 months.
|
Records of adverse events occurring in the follow-up period: including subconjunctival hemorrhage, infection, increased intraocular pressure, retinal tear, retinal detachment, etc.
|
during the follow-up for up to 12 months.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Chenjin Jin, Ph.D, Zhongshan Ophthalmic Center, Sun Yat-sen University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Eye Diseases
- Retinal Degeneration
- Retinal Diseases
- Embolism and Thrombosis
- Venous Thrombosis
- Thrombosis
- Macular Degeneration
- Macular Edema
- Retinal Vein Occlusion
- Physiological Effects of Drugs
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Ranibizumab
Other Study ID Numbers
- 2019KYPJ092
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Retinal Vein Occlusion
-
University of TorontoOntario Research FundUnknownCentral Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Central Retinal Artery Occlusion | Branch Retinal Artery OcclusionCanada
-
University of TorontoPfizer; Unity Health Toronto; Canadian Heart Research Centre; Ontario Association... and other collaboratorsUnknownThrombosis | Central Retinal Vein Occlusion | Retinal Vein Occlusion | Branch Retinal Vein Occlusion | Retinal Vein ThrombosisCanada
-
Palo Alto Medical FoundationTerminatedCentral Retinal Vein Occlusion | Branch Retinal Vein OcclusionUnited States
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Tokyo Medical UniversityUnknownCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionJapan
-
Justis EhlersRegeneron PharmaceuticalsCompletedCentral Retinal Vein Occlusion | Diabetic Macular Edema | Retinal Vein Occlusion | Branch Retinal Vein OcclusionUnited States
-
Hoffmann-La RocheChugai PharmaceuticalCompletedCentral Retinal Vein Occlusion | Macular Edema | Hemiretinal Vein OcclusionUnited States, Korea, Republic of, Brazil, Japan, United Kingdom, China, Argentina, Australia, France, Hungary, Italy, Poland, Spain, Singapore, Austria, Czechia, Germany, Hong Kong, Israel, Portugal, Russian Federation, Taiwan
-
Anders KvantaCompletedCentral Retinal Vein OcclusionSweden
-
He Eye HospitalUnknownCentral Retinal Vein OcclusionChina
-
He Eye HospitalUnknownBranch Retinal Vein OcclusionChina
Clinical Trials on Ranibizumab
-
University of Campania "Luigi Vanvitelli"Completed
-
University of Illinois at ChicagoGenentech, Inc.WithdrawnGlaucoma | Neovascular Glaucoma | New Onset Glaucoma | New Onset Neovascular Glaucoma
-
Especialistas en Retina Medica y Quirurgica Grupo...Centro de Retina Medica y Quirurgica S.C.CompletedDiabetic Macular EdemaArgentina, Mexico
-
Hanscom, Thomas, M.D.Genentech, Inc.CompletedCentral Retinal Vein Occlusion | Macular Edema | Branch Retinal Vein OcclusionUnited States
-
Samsung Bioepis Co., Ltd.CompletedAge-Related Macular DegenerationKorea, Republic of, United States, India, Germany, Hungary, United Kingdom, Czechia, Poland, Russian Federation
-
Lupin Ltd.RecruitingNeovascular Age-related Macular DegenerationIndia
-
Hawaii Pacific HealthGenentech, Inc.CompletedPolypoidal Choroidal Vasculopathy | PCVUnited States
-
New England Retina AssociatesGenentech, Inc.CompletedChoroidal MelanomaUnited States
-
Peter A Campochiaro, MDGenentech, Inc.CompletedRetinal Vein OcclusionUnited States
-
Vista KlinikCompletedAge Related Macular Degeneration | Choroidal NeovascularizationSwitzerland